Alessandro ButtéLecturer and Senior Researcher
Fabian FeidlCo-founder, PhD Candidate ETH
Michael SokolovCo-founder, COO, Postdoc ETH
Dr. Casper GøtzscheCo-founder
Morten AlbrechtsenSenior Executive
Vadim FedulovPrincipal Scientist
The Bactaviva Project
Bactaviva offers novel services for prevention of disturbed gut flora through safe and convenient personalized fecal microbiota transplantation with capsules, and cutting edge microbiota analysis.
Medical procedures that compromise the immune defense carries a risk for opportunistic pathogens in the GI tract. With personalized fecal microbiota transplantation, using healthy autologus fecal microbiota, right after the completed medical procedure, this risk is markedly reduced.
The most pronounced medical need is recurrent Clostridium difficile infections (CDI). After broadspectrum antibiotics treatment about 25% get recurrent disease. Hospitalization is common with annual costs in acute-care facilities in the U.S. of 4.8 BUSD, and a mortality from recurrent CDI of 29,000 /year.
Fecal microbiota transplantation, FMT, has shown excellent treatment effects, but is expensive, cumbersome and inconvenient, not regulated by authorities and has a risk for transmission of infections and antibiotic resistant bacteria from donors.
The Bactaviva personalized FMT allows immediate implementation to prevent and treat microbiota dysbiosis cuased by antibiotics, traveller’s infections and to prevent resistant strains to establish. It is safe, cost-effective and very convenient for patients and health providers. The Bactaviva library of healthy 16S rRNA and DNA microbiomes will be a unique source of information.
A process for collection, analysis, storage and encapsulation has been established. A patent application was filed in January 2017.
With a grant from EIT Health a controlled clinical intervention study is planned for the next 6 months in volunteers comparing safety, and also microbiota recovery, after an antibiotics regimen.
We look for
Industrial investor(s) who can invest 2.5 + 2.5 M€ to establish laboratories, launch the services and actively contribute to internationalization.
Added values to sales will be the company’s market presence, KOL network and unique microbiome library; a good base for development and partnering.